-- ICU Expects Acquisition to be Accretive to 2009 Earnings --
-- Hospira to Focus Future Growth and Innovation in Streamlined Product Line --
SAN CLEMENTE, Calif., and LAKE FOREST, Ill., July 9 /PRNewswire-FirstCall/
-- ICU Medical, Inc., (Nasdaq: ICUI), a leading low-cost manufacturer of safe
medical connectors, custom medical products and critical care devices,
announced today that it has entered into a definitive purchase agreement to
acquire the commercial rights and physical assets of Hospira, Inc.'s (NYSE:
HSP) critical care product line for approximately $35 million in cash. The
acquisition is expected to close during the third quarter of 2009.
"This acquisition creates a long-term growth opportunity for ICU Medical
and positions us to improve gross margins and earnings by controlling all
aspects of the critical care product line," said Dr. George Lopez, chairman
and president, ICU Medical. "We have been manufacturing the majority of
Hospira's critical care offerings for over four years and Hospira continues to
be a very important partner for our company. Hospira's recent internal
initiatives have created a good opportunity for us to acquire this business.
This transaction will enable us to completely control worldwide commercial
responsibility for the critical care products including sales, marketing,
customer contracting and distribution."
"This agreement advances Hospira's Project Fuel optimization efforts to
simplify our product line," said Christopher B. Begley, chairman and chief
executive officer, Hospira. "It will enable an even greater focus on Hospira's
core strategic areas of specialty injectable pharmaceuticals (SIP) and
medication management systems (MMS), driving innovation and growth in these
key businesses. The strong partnership between Hospira and ICU Medical,
combined with ICU Medical's strength in the critical care market, will also
make this transition a smooth one for customers, and will facilitate continued
availability and future investment in these important critical care products."
In 2005, Hospira and ICU Medical entered into a strategic manufacturing,
commercialization and development agreement for Hospira's critical care
product line. As part of this previous agreement, ICU Medical also purchased
Hospira's Salt Lake City facility where the majority of Hospira's critical
care products are produced. Upon completion of the acquisition announced
today, ICU Medical will gain complete control of Hospira's critical care
product line and acquire the commercial rights to the products. To help
facilitate the transition process for Hospira's customers and employees, the
two companies are entering into transitional services agreements for up to 18
Dr. Lopez added, "We will continue to deliver the critical care products
to the existing customer base and we believe we are in a good position to
increase overall market penetration of these products by leveraging our
existing customers as well as strategic partnerships. We believe our leading
low-cost manufacturing combined with our expanding sales team positions us to
profitably increase our market share in critical care."
Scott Lamb, ICU Medical's Chief Financial Officer, said, "Our strong cash
flow and balance sheet enable us to increase our product offerings and further
expand our geographic footprint both organically and through strategic
acquisitions. This acquisition is a natural progression for our company in
the critical care market and we are very pleased with the long-term
opportunities it provides."
ICU Medical ended the first quarter with a very strong balance sheet. As
of March 31, 2009, cash, cash equivalents and investment securities totaled
$141.9 million, it had no long-term debt, and working capital was $170.1
million. Additionally, ICU Medical achieved operating cash flow of $19.8
million for the first quarter of 2009.
ICU Medical Fiscal Year 2009 Guidance
ICU Medical expects this acquisition to be accretive to its earnings in
2009. It will update full-year 2009 revenue and earnings guidance on its
second-quarter earnings call, currently scheduled for the third week of July,
About ICU Medical, Inc.
ICU Medical, Inc. (Nasdaq: ICUI) is a leader in the development,
manufacture and sale of proprietary, disposable medical connection systems for
use in vascular therapy applications. ICU Medical's devices are designed to
protect patients from catheter related bloodstream infections and healthcare
workers from exposure to infectious diseases through accidental needle sticks
or hazardous drugs. It is also a leader in the production of custom I.V.
systems and incorporates proprietary products into many of those custom I.V.
systems. For more information, visit www.icumed.com.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness(TM). As the world leader in specialty
generic injectable pharmaceuticals, Hospira offers one of the broadest
portfolios of generic acute-care and oncology injectables, as well as
integrated infusion therapy and medication management solutions. Through its
products, Hospira helps improve the safety, cost and productivity of patient
care. The company is headquartered in Lake Forest, Ill., and has more than
14,000 employees. Learn more at www.hospira.com.
This press release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such statements contain words
such as "will," "expect," "believe," "could," "would," "estimate," "continue,"
"build," "expand" or the negative thereof or comparable terminology, and may
include (without limitation) information regarding ICU Medical's or Hospira's
expectations, market penetration, goals or intentions regarding the future,
including, but not limited to, ICU Medical's expectation that the acquisition
will be accretive to its earnings in 2009; the creation of long-term growth
opportunities for ICU Medical and its positioning for improvements to its
gross margins and earnings; ICU Medical's ability to control worldwide
commercial responsibility for its critical care products; the belief that the
strong partnership between ICU Medical and Hospira and ICU Medical's strength
in the critical care market will make the transition smooth for customers and
will facilitate continued availability and future investment in critical care
products; ICU Medical's continued delivery of critical care products and
positioning to increase its overall market penetration; the profitable
increase of ICU Medical's market share in critical care; the expectation that
the acquisition will close in the third quarter of 2009. These forward-looking
statements are based on current expectations, estimates, forecasts and
projections and assumptions believed to be reasonable by the management of the
party making such statements, all of which are subject to risks and
uncertainties that could cause actual results and events to differ materially
from those stated in the forward-looking statements. These risks and
uncertainties include, but are not limited to: growing or declining demand for
our products; investments in strategic growth; continued growth; third-party
regulations or approvals; increased competition; unforeseen litigation or
outcomes of litigation and improving efficiencies. Future results are subject
to risks and uncertainties, including the risk factors, and other risks and
uncertainties described in ICU Medical's and Hospira's respective filings with
the Securities and Exchange Commission, including the respective Annual
Reports on Form 10-K for the year ended December 31, 2008, Quarterly Reports
on Form 10-Q for the quarter ended March 31, 2009 and other current and
periodic reports filed with or furnished to the Securities and Exchange
Commission from time to time. Forward-looking statements contained in this
press release are made only as of the date hereof, and ICU Medical and Hospira
undertake no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise.
SOURCE Hospira, Inc.; ICU Medical, Inc.
Media and Financial Community,
Officer of ICU Medical, Inc.,
Director of ICR, Inc.,
for ICU Medical, Inc.;
Financial Community, Karen King,
both of Hospira, Inc.
Web Site: http://www.hospira.com